TC LPA5 4

TC LPA5 4 is an antagonist of lysophosphatidic acid receptor 5 (LPA5, IC50 = 0.8 µM in McA-RH7777 cells expressing the human receptor). It selectively inhibits the aggregation of washed isolated human platelets induced by 16:0 alkyl-LPA (1-palmitoyl LPA, Cay-10010094, Cay-10010290) over collagen or thrombin receptor activating peptide (TRAP, IC50s = 0.8, >10, and >10 µM, respectively). TC LPA5 4 also inhibits the histone-lysine N-methyltransferase NSD2 (IC50 = 8.5 µM) and 29 other methyltransferases (IC50s = 0.33-71 µM). It reduces tumor volume in a CGTH-W-3 thyroid cancer mouse xenograft model when administered at a dose of 10 mg/kg. TC LPA5 4 (10 mg/kg, i.p.) prevents brain tissue loss and neurological deficits, as well as increases survival, neurogenesis in the subventricular zone, and angiogenesis in the penumbra, in a mouse model of ischemic stroke induced by transient middle cerebral artery occlusion (MCAO).Formal Name: 5-(3-chloro-4-cyclohexylphenyl)-1-(3-methoxyphenyl)-1H-pyrazole-3-carboxylic acid. CAS Number: 1393814-38-4. Synonyms: TC Lysophosphatidic Acid Receptor 5 4. Molecular Formula: C23H23ClN2O3. Formula Weight: 410.9. Purity: >98%. Formulation: (Request formulation change), A solid. Solubility: Acetonitrile: Soluble, DMSO: Soluble. SMILES: ClC1=C(C2CCCCC2)C=CC(C3=CC(C(O)=O)=NN3C4=CC=CC(OC)=C4)=C1. InChi Code: InChI=1S/C23H23ClN2O3/c1-29-18-9-5-8-17(13-18)26-22(14-21(25-26)23(27)28)16-10-11-19(20(24)12-16)15-6-3-2-4-7-15/h5,8-15H,2-4,6-7H2,1H3,(H,27,28). InChi Key: BNALUYKEGYUHQC-UHFFFAOYSA-N.